Life Science Nation Newsletter | November 29, 2018 | Issue 294


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI San Francisco 2019
   Life Science Investor Mandates
(Nov. 22 - Nov. 28 )
Seeks to Invest in Devices & Digital Health Technologies in Behavioral Health
Invests Up to $10M in Novel Early-Stage Therapeutics
Actively Investing in Cutting-Edge Therapeutics and Diagnostics Technologies in Oncology & CNS
Seeks Therapeutics Investment Opportunities in All Indications
News
LSN Services
LSN Videos
LSN Media Partners
By Greg Mannix, VP of International Business Development, LSN

RESI works! Below are two successful fundraising CEOs that have received capital allocations from investors met at RESI. Both executives have used RESI to find investors with vetted mandates that are a fit for their technology and stage of development.

David Narrow is CEO at Sonavex, an innovative MedTech firm out of Baltimore that has successfully raised Seed, Grant and Series A funding to advance the development and regulatory approvals of its EchoMark imaging devices. David has been to many RESIs over the last few years, with great success. Greg Mannix, LSN's VP of International Business Development, interviewed David to learn more about his experiences at RESI and the strategies he employs to get the most out of the conference.

Greg Mannix: David, you've been to quite a few RESI conferences starting in mid 2016: what has that been like for you? 
David Narrow: RESI is a really efficient way to have a lot of vetted meetings with investors. I have had many fruitful discussions with investors at the different RESIs I have attended, which is why I continue to attend. It is a great place to meet investors that were not on our radar and get exposure to smaller and sometime less well-known funds. 

GM: You recently raised some money. Can you tell me the role RESI has played in your fundraising strategy? 
DN: Yes, we actually met one of the key investors in our Series A round through RESI-Fusion Fund-and we are still in discussions with several other investors. We are planning for our Series B and will be attending the next RESI at JPM...

Kasper Roet is CEO at QurAlis, a new private biotech company focused on developing precision solutions to cure ALS and FTD. The company recently closed a new seed round of funding, so Greg Mannix, VP International Business Development at LSN, wanted to talk to Kasper about his experience at the RESI conference.

Greg Mannix: How did you hear about LSN and RESI?
Kasper Roet: I heard about it from my friend Thomas Forest Farb, who is CEO at Thrive Biosciences.

GM: How many RESIs have you attended or will attend?
KR: The RESI in June in Boston was the first I attended, but I may attend more in the future...

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN announces the launch of the Focus on Cures Accelerator in Boston and will offer its first 2-week Immersion Course in the first quarter of 2019. The program is aimed at top life science companies from outside the US who are developing technologies in the four "Ds"-Drugs, Devices, Diagnostics and Digital Health-and are looking to connect with the global investor ecosystem as well as explore the leading Boston/Cambridge life science hub for future business development in the United States.

The program will be absolutely unique because of LSN's deep resources: investor and company data platforms that are unparalleled in the life sciences arena, the RESI conference series-laser-focused on early stage funding, Boston Innovation Capital investment banking experience and all of the contacts, connections and channel partners accumulated and curated over the years.

The FOC Accelerator 2-week Immersion Course will provide the following benefits:

Your office in Boston

Use of the LSN coworking space in Downtown Boston

Mentorship
  • Tactical advice on how the cross-border global partnering arena works
  • A thorough understanding of the ten categories of early stage investors and partners including family offices, foundations, endowments, angel investors, venture capitalists, private equity, strategic pharma, corporate venture, government and hedge funds...

By Karen Deyo, Investor Research Analyst, LSN

This January will feature our 21st RESI conference in San Francisco during JPM. The RESI conference series has been held in multiple cities across North America and has grown to be the conference of reference for early-stage funding, with many companies attending multiple conferences to help form connections with potential investors and strategic partners and many investors utilizing RESI as a good source of quality deal flow. LSN's global network of companies and investors have been calling for RESI to expand outside of North America, and it is with great excitement that we announce RESI Europe, taking place on March 25th in Vienna, Austria. We are looking forward to bringing a full day of partnering meetings, panels and workshops to the global stage. Registration will open next week. For more information, please contact resi@lifesciencenation.com. We hope to see you in Vienna!



Created & Produced by